Track topics on Twitter Track topics that are important to you
Despite a crisis of confidence in AstraZeneca last week, its checkpoint inhibitor, Imfinzi, just got FDA endorsement in NSCLC. Just last week, AstraZeneca saw its stock value drop by 15% — a hit to the market cap that equates to ...
This awesome article AstraZeneca’s Checkpoint Inhibitor Scores a Win in Lung Cancer After Last Week’s Failure appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)NEXT ARTICLE
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009. it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...